fosbretabulin tromethamine | |
---|---|
Trade Name | |
Orphan Indication | Neuroendocrine tumors |
USA Market Approval | USA |
USA Designation Date | 2015-12-29 00:00:00 |
Sponsor | Mateon Therapeutics, Inc.;701 Gateway Blvd, Suite 210;South San Francisco, California, 94080 |